SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...
As of Monday, December 29, Ovid Therapeutics Inc.’s OVID share price has dipped by 5.90%, which has investors questioning if ...
A research team has developed a sustainable, metal-free carbon catalyst derived from marine biomass that efficiently removes persistent antibiotic pollutants from water.
The epidemiology of hypertension in India has undergone a malignant shift, moving from a disease of the elderly to a ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of ...
Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
After taking over the reins of Beauty editor at Weekend in June, Sally Foran has tried dozens of treatments to recommend the ...
University of Colorado Boulder researchers document how the zero-calorie sweetener triggers cellular changes in brain vessels ...
7h
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback